Article Information
History
- November 30, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
Author Information
- Hamzah Z Farooq1,2,3,
- Vanessa Apea1,2,3,
- Bakita Kasadha4,
- Sadna Ullah1,2,3,
- Gill Hilton-Smith5,
- Amber Haley5,
- Jenny Scherzer5,
- James Hand1,3,
- Sara Paparini1,6,
- Rachel Phillips7 and
- Chloe Orkin1,2,3,*
- 1SHARE Collaborative, Queen Mary University of London, London, UK
- 2Blizard Institute, Queen Mary University of London, London, UK
- 3Department of Infection and Immunity, Barts Health NHS Trust, London, UK
- 4Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK
- 5ViiV Healthcare, Middlesex, UK
- 6Wolfson Institute of Population Health, Queen Mary, University of London, London, UK
- 7Pragmatic Clinical Trials Unit, Centre for Evaluation & Methods, Wolfson Institute of Population Health Queen Mary University of London, London, UK
- ↵*Corresponding Author:
Professor Chloe M Orkin, Email - c.m.orkin{at}qmul.ac.uk, Address:
SHARE Collaborative, Blizard Institute, Queen Mary University of London, 4 Newark St, London, E1 2AT, UK
Posted November 30, 2022.
The ILANA study: a paradigm shift in ensuring equity of clinical implementation in HIV research
